Global medical technology company Becton, Dickinson, and Company (BD; Franklin Lakes, NJ) has agreed to pay $350 million for the approximately 93.5% of outstanding shares in TriPath Imaging (Burlington, NC), a leading player in the increasingly crowded market for cervical cancer screening. BD has held a 6.5% equity interest in TriPath since 2001, when the two companies began their ongoing collaboration to discover cancer biomarkers.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

October 2006 - Table of Contents

LIR October 2006 (full PDF issue)

Hospital Outreach Programs Hold Their Own Against Key Competitors

Acquisition Is Path to Market Share in Southeast

Measuring Up Against Quest and LabCorp: Inside the Duopoly

Quest Pays $43m for InSure Test Maker

Psychemedics, Orchid Land New Contracts

AMGA Survey Finds Most Medical Groups Still Operating at a Loss

BD to Pay $350 Million for Pap Test Maker TriPath

Laposata Wins G-2 Laboratory Public Service National Leadership Award

Lab Stocks Down 1%; Monogram Loses 13%

Get an Edge at LabCompete